Cell Source Inc is a biotechnology company focused on developing cell therapy treatments focused on immunotherapy. The company's subsidiary commercializes a suite of inventions relating to certain cancer treatments. Its other products include Anti-rejection Veto Cell tolerance therapy for both matched and mismatched allogeneic bone marrow transplantations and Anti-rejection Veto Cell tolerance therapy for both matched and mismatched organ transplantation.
Quote | Cell Source Inc (OTCMKTS:CLCS)
Last: | $0.39 |
---|---|
Change Percent: | -2.86% |
Open: | $0.36 |
Close: | $0.39 |
High: | $0.39 |
Low: | $0.36 |
Volume: | 1,180 |
Last Trade Date Time: | 08/02/2024 03:00:00 am |
News | Cell Source Inc (OTCMKTS:CLCS)
In recent years, biomedical research on topics surrounding longevity and aging has gained a tremendous amount of traction. The biotech industry as well as major pharmaceutical companies, have also jumped onto the bandwagon of discovering ways to alter and reverse the aging process. Currently, ...
Darlene Soave Joins Cell Source's Board of Directors PR Newswire NEW YORK , April 1, 2021 /PRNewswire/ -- Cell Source, Inc. (OTC: CLCS) ( " Cell Source" or "the Company"), is the world leader in Veto Cell based innovative immunotherapy and today announced tha...
Message Board Posts | Cell Source Inc (OTCMKTS:CLCS)
Subject | By | Source | When |
---|---|---|---|
$CLCS nice move- looks like a walkup or | protagonist12 | investorshub | 04/12/2015 9:23:35 PM |
Emylers: CLCS Financials 07/16/2014 08:37:58 Cell Source, Inc. Period Ending Dec 31, 2013 Dec 31, 20 | Emylers | investorshangout | 07/16/2014 1:37:54 PM |
News, Short Squeeze, Breakout and More Instantly...
In recent years, biomedical research on topics surrounding longevity and aging has gained a tremendous amount of traction. The biotech industry as well as major pharmaceutical companies, have also jumped onto the bandwagon of discovering ways to alter and reverse the aging process. Currently, ...
Darlene Soave Joins Cell Source's Board of Directors PR Newswire NEW YORK , April 1, 2021 /PRNewswire/ -- Cell Source, Inc. (OTC: CLCS) ( " Cell Source" or "the Company"), is the world leader in Veto Cell based innovative immunotherapy and today announced tha...
USPTO Issues New Patents for Cell Source's Veto Cell Technology Patents Validate Veto Cells as a Critical Enabler for Cell Therapies Such as CAR-T, TCR, and NK as well as a Powerful, Stand-alone Immunotherapy in the Treatment of Cancer, Viral and Bacterial Infections PR News...